NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer

Summary

RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy with Everolimus is in treating subjects with triple negative breast cancer who have residual disease after chemotherapy.

Timeline

Start

2013-07

Primary completion

2019-01

Completion

2019-01

Publications

• Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep. 2021 Jan 8;11(1):82. doi: 10.1038/s41598-020-80081-y.

Drugs

Indications